Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from Chardan Capital

Coya Therapeutics (NASDAQ:COYA - Get Free Report)'s stock had its "buy" rating reaffirmed by Chardan Capital in a research report issued on Tuesday,Benzinga reports. They presently have a $14.00 price target on the stock. Chardan Capital's target price would indicate a potential upside of 123.46% from the stock's previous close.

A number of other research firms also recently commented on COYA. Wall Street Zen downgraded shares of Coya Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. D. Boral Capital reissued a "buy" rating and set a $18.00 target price on shares of Coya Therapeutics in a report on Tuesday, April 22nd. Finally, HC Wainwright restated a "buy" rating and issued a $18.00 target price on shares of Coya Therapeutics in a research report on Monday, June 9th.

Coya Therapeutics Price Performance

Shares of NASDAQ COYA traded up $0.49 during midday trading on Tuesday, hitting $6.27. 72,677 shares of the company's stock were exchanged, compared to its average volume of 72,346. Coya Therapeutics has a twelve month low of $4.65 and a twelve month high of $10.24. The firm has a market cap of $104.81 million, a P/E ratio of -5.86 and a beta of 0.26. The stock's 50 day moving average price is $5.83 and its 200-day moving average price is $5.99.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.44). The business had revenue of $257.88 million for the quarter, compared to analyst estimates of $2.63 million. On average, analysts expect that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Hedge Funds Weigh In On Coya Therapeutics

Several large investors have recently made changes to their positions in the business. Jane Street Group LLC bought a new stake in shares of Coya Therapeutics in the 4th quarter worth approximately $74,000. Tower Research Capital LLC TRC grew its position in Coya Therapeutics by 1,005.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company's stock worth $30,000 after buying an additional 4,777 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Coya Therapeutics by 12.2% in the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company's stock valued at $164,000 after buying an additional 3,099 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Coya Therapeutics by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 150,576 shares of the company's stock valued at $863,000 after acquiring an additional 8,267 shares during the last quarter. Finally, AIGH Capital Management LLC lifted its position in shares of Coya Therapeutics by 85.0% during the 4th quarter. AIGH Capital Management LLC now owns 1,201,152 shares of the company's stock valued at $6,883,000 after acquiring an additional 551,725 shares during the last quarter. Institutional investors own 39.75% of the company's stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.